Previous reports suggested that specific targeting of CCR5 in human autologous CD4+ T cells by ZFN, TALEN or CRISPR/SpCas9  protected against HIV-1 infection [13, 15, 30–32]. This evidence concerns the gene CD4 and HIV-1 infection.